KLRK1 and chronic myelogenous leukemia, BCR-ABL1 positive: In the context of chronic myelogenous leukemia (CML), the activation of Vγ9Vδ2 T cells by zoledronate was shown to increase anti-leukemia activities in a NKG2D-dependent manner, notably in CML-resistant patients (48).